RxDoctor Payments Data

Alan Carnes, MD

Urology · Watkinsville, GANPI 1295140747

Payments from drug & device makers

$6,387in general payments, 2019–2025

Across 227 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$873
  • Bayer$635
  • Johnson & Johnson$541
  • Boston Scientific$477
  • Teleflex LLC$420
  • Astellas Pharma US Inc$356
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$5969%
  • Food & beverage$5,75790%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,387 in reported general payments places this provider in the 60th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$247,035
Medicare patients
625
Services billed
5,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix96$251,248
MyrbetriqMirabegron99$58,706
GemtesaVibegron35$31,200
Dutasteride54$3,683
Tamsulosin Hcl335$3,291
Fesoterodine Fumarate ErFesoterodine Fumarate33$1,649
Testosterone15$1,479
Finasteride122$1,330
Testosterone Cypionate42$1,296
Silodosin11$1,131
Estradiol14$846
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$808
Methenamine Hippurate28$802
Oxybutynin Chloride ErOxybutynin Chloride70$767
NitrofurantoinNitrofurantoin Macrocrystal22$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$252$282,448131 claims
Astellas Pharma US IncMyrbetriq$356$58,70699 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 369 urology providers in Georgia.

Other urology in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →